Denali Therapeutics Inc (NASDAQ: DNLI) kicked off on Tuesday, up 0.29% from the previous trading day, before settling in for the closing price of $13.83. Over the past 52 weeks, DNLI has traded in a range of $10.57-$33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -4.46%. While this was happening, its average annual earnings per share was recorded -18.34%. With a float of $125.73 million, this company’s outstanding shares have now reached $145.25 million.
Let’s determine the extent of company efficiency that accounts for 422 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 13.46%, while institutional ownership is 92.28%. The most recent insider transaction that took place on Jul 09 ’25, was worth 7,429,230. In this transaction President and CEO of this company sold 495,282 shares at a rate of $15.00, taking the stock ownership to the 253,071 shares. Before that another transaction happened on Jul 09 ’25, when Company’s Officer proposed sale 495,282 for $14.33, making the entire transaction worth $7,097,391.
Denali Therapeutics Inc (DNLI) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -18.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.54% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Take a look at Denali Therapeutics Inc’s (DNLI) current performance indicators. Last quarter, stock had a quick ratio of 9.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.77 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Looking closely at Denali Therapeutics Inc (NASDAQ: DNLI), its last 5-days average volume was 1.49 million, which is a jump from its year-to-date volume of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 6.73%.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 36.87%, which indicates a significant increase from 10.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.68 in the past 14 days, which was lower than the 0.90 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.23, while its 200-day Moving Average is $19.24. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $14.08. Second resistance stands at $14.29. The third major resistance level sits at $14.48. If the price goes on to break the first support level at $13.68, it is likely to go to the next support level at $13.49. Now, if the price goes above the second support level, the third support stands at $13.28.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
The company with the Market Capitalisation of 2.01 billion has total of 145,276K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -422,770 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -132,970 K.
